	Review of radiopharmaceutical therapy in prostate cancer. Urol Oncol Miller SR, Dewaraja Y, Rowe SP, Reichert ZR, Viglianti BL. PMID: 41714269 [PubMed - as supplied by publisher]
	Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study. Eur Urol Bancroft EK, Page EC, McHugh J, Thomas S, Taylor N, Pope J, Evans DG, Rothwell J, Grindedal EM, Maehle L, James P, McKinley J, Mascarenhas L, Side L, Thomas T, van Leerdam ME, van Asperen CJ, Kiemeney LALM, Ringelberg J, Vlaming M, Rønlund K, Osther PJS, Helfand BT, Hutten CG, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Salinas M, Feliubadaló L, Oosterwijk JC, van Zelst-Stams WAG, Cook J, Rosario DJ, Maxwell K, Powers J, Buys S, Lyman J, Ausems MGEM, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, Davidson R, Longmuir M, Ruijs MWG, Blom EW, van Engelen K, Williams R, Andrews L, Murphy DG, Saya S, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Snape K, Gowie M, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Cajal TRY, Krajc M, Cleaver R, Cruellas M, Perez-Ballestero E, Brady AF, Gallagher D, Donaldson A, Barwell J, Nicolai N, Friedman E, Hall MJ, Greenhalgh L, Murthy V, Copakova L, McGrath JS, Cooke P, Arun B, Myhill K, Hogben M, Hussain S, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Falconer A, Gronberg H, Hamdy FC, Khoo V, Lilja H, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Offman J, Rennert G, Suri M, Dudderidge T, IMPACT Study Collaborators, Brook MN, Kote-Jarai Z, Eeles RA. PMID: 41714267 [PubMed - as supplied by publisher]
	Neoadjuvant therapy in gall bladder cancer improves resectability and survival: a prospective study. HPB (Oxford) Lahiri A, Chowdhury S, Goel S, Assif Iqbal S, Aggarwal A, Garg P, Goel V, Talwar V, Sethi J, Singh S. PMID: 41714243 [PubMed - as supplied by publisher]
	Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration). Eur Urol Focus Halabi S, Luo B, Yu C, Rydzewska LHM, Roy A, Kim H, Godolphin PJ, Murphy L, Carducci MA, Gravis G, Sfumato P, Boher JM, James ND, Tierney JF, Page D, Sweeney C, Guo S. PMID: 41714204 [PubMed - as supplied by publisher]
	Differential Response to (177)Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer. J Nucl Med Pepin A, Doucette A, Narayan VK, Maxwell KN, Takvorian SU, O'Brien SR, Mankoff DA, Mulugeta PG, Taunk NK. PMID: 41714123 [PubMed - as supplied by publisher]
	Outcomes of a Phase II Interventional Clinical Trial of Prostate Bed Stereotactic Body Radiation Therapy for Prostate Cancer with High-Risk Features Following Radical Prostatectomy. Int J Radiat Oncol Biol Phys Vargas CE, Voss MM, Dodoo C, Wong W, Zhu A, Keole SR, Rwigema JC, Davis B, Stish BJ, Laughlin B, Daniels T. PMID: 41713512 [PubMed - as supplied by publisher]
	Efficacy and tolerability of hypofractionated and dose-boosted radiotherapy for localised prostate cancer: a systematic review and meta-analysis. Radiother Oncol Miszczyk M, Sohoni N, Smani S, Moll M, Alfarhan AR, Roessler N, Miyajima K, Inoue S, Marvaso G, Mastroleo F, Zamboglou C, Soeterik TF, Zilli T, Terlizzi M, Blanchard P, Rajwa P, Fazekas T, Ploussard G, An Y, Leapman MS, Blanck O, Jereczek-Fossa BA, Shariat SF. PMID: 41713502 [PubMed - as supplied by publisher]
	Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study. Lancet Oncol Soeterik TFW, Miszczyk M, Peters M, Bilski M, Francolini G, Garlatti P, Nicosia L, Alongi F, Mezeckis M, Kociolek J, Greco C, Techma, Huele EH, Teunissen FR, Westhoff PG, Vis W, Haverkort MAD, van der Voort van Zyp JRN, Intven MPW, van der Velden JM, Shariat SF, Eppinga WSC. PMID: 41713474 [PubMed - as supplied by publisher]
	[Multidisciplinary management of elderly patients with advanced prostate cancer]. Rev Esp Geriatr Gerontol Molina-Garrido MJ, Ramírez-Martín R, Sánchez Castellano C, Cruz Castellanos P, Sánchez García M, Ríos González E, de Cabo Ripoll M, Martín Ordóñez F, Acosta Rojas Á, Arribas L, Cassinello J. PMID: 41713351 [PubMed - as supplied by publisher]
	Microvessel density as a prognostic factor in renal cell carcinoma: A systematic review and meta-analysis with individual patient data reconstructed from previous Kaplanâ€’Meier curves. Cancer Treat Res Commun Sun S, Zhang H, Ma L. PMID: 41713310 [PubMed - as supplied by publisher]
	Survival Prediction in Patients With Bladder Cancer Undergoing Radical Cystectomy Using a Machine Learning Algorithm: Retrospective Single-Center Study. JMIR Perioper Med Causio FA, De Vita V, Nappi A, Sawaya M, Rocco B, Foschi N, Maioriello G, Russo P. PMID: 41712865 [PubMed - indexed for MEDLINE]
	Contrast-enhanced US Evaluation of Indeterminate Focal Renal Masses. Radiographics Desai MA, Alexander LF, Clingan MJ, Thompson CP, Patel NJ, Barbee VV, Cox KL, Agely A, Gu CN, Caserta MP. PMID: 41712443 [PubMed - indexed for MEDLINE]
	Apalutamide + Abiraterone acetate plus Prednisone (AAP) + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase 2 Study. Clin Cancer Res McBride SM, Spratt DE, Kollmeier M, Abida W, Xiao H, Slovin SF, Paller CJ, Deville C, Den RB, Hearn J, Catharine V, Scher H, Zelefsky M, Rathkopf D. PMID: 41712259 [PubMed - as supplied by publisher]
	Learning anatomy from unlabelled CT volumes: A self-supervised framework for improving prostate radiotherapy segmentation. Med Phys Hizam DA, Ung NM, Saad M, Salleh FM, Muaadz A, Tan LK. PMID: 41712191 [PubMed - indexed for MEDLINE]
	Impact of frailty on overall survival and complications in patients with prostate cancer: a systematic review and meta-analysis. Int Urol Nephrol Chen Q, Wu J, Cai Q. PMID: 41712034 [PubMed - as supplied by publisher]
	Thrombosis-related gene signature predicts prostate cancer recurrence and immune therapy: insights from retrospective cohorts, bioinformatics, and experimental validation. Inflamm Res Luo Y, Chen P, Situ M, Zhuang W, Huang J, Wang B, Wang Q, Peng S, Huang H. PMID: 41711904 [PubMed - indexed for MEDLINE]
	[The OPTIMUM trial: microultrasonography-guided vs MRI-guided biopsy for prostate cancer diagnosis]. Urologie Cash H, Borkowetz A. PMID: 41711899 [PubMed - as supplied by publisher]
	MRI-based habitat radiomics for assessing synchronous metastatic risk in renal cell carcinoma: a multicenter study. Abdom Radiol (NY) Bai X, Xu H, Zhou S, Jia T, Yi S, Zhao H, Xie L, Liu B, Liu X, Liu H, Mu X, Zhang M, Zhao J, Ye H, Ma X, Wang H. PMID: 41711878 [PubMed - as supplied by publisher]
	Thyroid cartilage resection surgery for metastases of clear cell renal cell carcinoma: case report and literature review. Einstein (Sao Paulo) Lisboa LZ, Cunha GBD, Pinheiro MLP, Haddad L, Ceccon FP. PMID: 41711787 [PubMed - indexed for MEDLINE]
	Copper-based architectures for bladder cancer therapy: mechanistic insights, progress and prospects. Nanoscale Zhang P, Xiong W, Wang K, Zhao X, Liu X, Huang M. PMID: 41711555 [PubMed - as supplied by publisher]

Articles 1 - 20 / 176143

Page 1 of 8808



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy